SalT Reduction InterVEntion: Metabolic, Behavioral and Health Consequences of Reducing Salt in Bread (STRIVE)

July 11, 2019 updated by: Ulla Toft, Bispebjerg Hospital

SalT Reduction InterVEntion: Examination of the Metabolic, Behavioral and Health Consequences of Reducing Salt Intake. A Randomized Controlled Trial in a Real Life Setting

The trial is conducted as a randomized controlled trial including children and adults recruited as families. The families are randomly allocated into three groups to investigate the effect of different salt reduction strategies in a period of 3-4 months. Families in the first intervention group are receiving salt reduced bread. Families in the second intervention group are receiving salt reduced bread in combination with dietary counselling to reduce salt and increase potassium intake. Families in the control group are receiving bread with a regular content of salt and no dietary counselling.

Study Overview

Detailed Description

The trial is conducted as a randomized controlled trial including children and adults recruited as families. The families are randomly allocated into three groups to investigate the effect of different salt reduction strategies in a period of 3-4 months. Families in the first intervention group are receiving salt reduced bread. Families in the second intervention group are receiving salt reduced bread in combination with dietary counselling to reduce salt and increase potassium intake. Families in the control group are receiving bread with a regular content of salt and no dietary counselling.

Participants will be instructed to replace their usual consumption of bread by the bread products provided in the study. In all other respects, participants will be requested to live their lives as usual without changing any habits, except the families receiving dietary counselling. The participants will be unaware of the treatment groups and the salt content of the bread products will be blinded to the participants.

Families will attend a physical examination at baseline and at 3-4 months follow-up. The health examination includes anthropometrics, blood pressure measurements and blood samplings for analysis of glucose, lipid metabolism and hormone balance. Urine samples will be collected to investigate the sodium and potassium content. Furthermore salt-sensitivity and preference tests will be made. After both health examinations the families will collect three repeated 24-hour urine collections at home and fill in a 7 days dietary record.

After data collection, blood and urine samples will be analysed. Analyses from both baseline and follow-up are expected ultimo February 2019, whereby data cleaning and statistical analyses will be performed.

Study Type

Interventional

Enrollment (Actual)

316

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Capital Region
      • Glostrup, Capital Region, Denmark, 2600
        • Center fot Clinical Research and Prevention

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 69 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants living with children
  • Adults 18-69 years
  • Children 3-17 years
  • Daily intake of bread

Exclusion Criteria:

  • Diabetes
  • Cardiovascular disease
  • Antihypertensive treatment
  • Lipid-lowering treatment
  • Pregnancy
  • U-albumin > 300 mg/day
  • Celiac disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Salt reduced bread
Bread with reduced salt content
Bread with gradually lowered salt content
Experimental: Dietary advice and Salt reduced bread
bread with reduced salt content, dietary advice
Bread with gradually lowered salt content
Participants will receive information on how to lower salt and increase potassium intake
Placebo Comparator: Normal bread
Bread with standard salt content
Bread with normal salt content

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline sodium level in 24 hour urine at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Adults average of 3 repeated 24 hour urine, children a single 24hour urine collection; excluding urine first morning including urine of the following morning. Completeness evaluated in adults by Para-Amino-Benzoic-Acid (PABA).
Measurements at Baseline and at 4 month.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline potassium level in 24 hour urine at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Adults average of 3 repeated 24 hour urine, children a single 24hour urine collection; excluding urine first morning including urine of the following morning.
Measurements at Baseline and at 4 month.
Change from Baseline Systolic blood pressure at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Systolic blood pressure measured at baseline and follow-up . Average of three measurements, with the participant sitting upright at rest.. Minimum 2 hours fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Diastolic blood pressure at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Diastolic blood pressure measured at baseline and follow-up . Average of three measurements, with the participant sitting upright at rest.. Minimum 2 hours fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Adrenaline and Noradrenaline levels in plasma at 4 months
Time Frame: Measurements at Baseline and at 4 month.
blood sampled, stored on ice, with the participant lying down after 30 minutes of rest. Minimum 2 hours of fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Renin and Aldosterone levels in plasma at 4 months
Time Frame: Measurements at Baseline and at 4 month.
blood sampled, with the participant lying down after 30 minutes of rest. Minimum 2 hours of fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Salt sensitivity and preference at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Sensory test: Sensitivity and preference test, minimum 2 hours of fasting
Measurements at Baseline and at 4 month.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline Glucose levels in plasma at 4 months
Time Frame: Measurements at Baseline and at 4 month.
blood sampled, with the participant lying down after 30 minutes of rest. Minimum 2 hours of fasting.
Measurements at Baseline and at 4 month.
Change from Baseline HbA1C levels in full blood at 4 months
Time Frame: Measurements at Baseline and at 4 month.
blood sampled, with the participant lying down after 30 minutes of rest. Minimum 2 hours of fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Cholesterol levels in plasma (LDL, HDL, total cholesterol and triglycerides) at 4 months
Time Frame: Measurements at Baseline and at 4 month.
blood sampled, with the participant lying down after 30 minutes of rest. Minimum 2 hours of fasting.
Measurements at Baseline and at 4 month.
Change from Baseline Height in centimetres at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Measured in centimetres to the closest decimal, without shoes or socks, with clothes on
Measurements at Baseline and at 4 month.
Change from Baseline Weight in kilograms at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Measured in kilograms to the closest decimal, without shoes or socks, with clothes on
Measurements at Baseline and at 4 month.
Change from Baseline Impedance in ohm at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Measured in ohm to the closest decimal, without shoes or socks, with clothes on
Measurements at Baseline and at 4 month.
Change from Baseline Hip circumference in centimetres at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Measured on bare skin to nearest decimal
Measurements at Baseline and at 4 month.
Change from Baseline Waist circumference in centimetres at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Measured on bare skin to nearest decimal
Measurements at Baseline and at 4 month.
Baseline Albumin in spot urine
Time Frame: Measurements at Baseline
Not morning urine, minimum 2 hours of fasting
Measurements at Baseline
Change from Baseline Sodium, potassium and creatinine level in spot urine at 4 months
Time Frame: Measurements at Baseline and at 4 month.
Not morning urine, minimum 2 hours of fasting
Measurements at Baseline and at 4 month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ulla Toft, MSc, PhD, Capital Region, Copenhagen, Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2018

Primary Completion (Actual)

April 30, 2019

Study Completion (Actual)

April 30, 2019

Study Registration Dates

First Submitted

November 30, 2018

First Submitted That Met QC Criteria

January 17, 2019

First Posted (Actual)

January 22, 2019

Study Record Updates

Last Update Posted (Actual)

July 12, 2019

Last Update Submitted That Met QC Criteria

July 11, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • H-17030995

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Salt Intake

Clinical Trials on Bread with reduced salt content

3
Subscribe